18 June 2021 - Second new drug application approved for Sulanda in China.

HutchMed today announces that surufatinib has been granted approval for drug registration by the National Medical Products Administration of China for the treatment of advanced pancreatic neuroendocrine tumours.

This approval was supported by SANET-p, a Phase 3 pivotal trial in patients with advanced pancreatic neuroendocrine tumours conducted in China.

Read HutchMed press release